Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 79 recruiting now early-phase tilt #50 of 28,707 conditions

Type 1 Diabetes: early-phase trial registry

79 of 199 indexed Type 1 Diabetes trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #50 of 28,707 conditions by registered trial count.

199 US clinical trials · 79 currently recruiting · #50 of 28,707 conditions by registered trial count

Type 1 Diabetes: 199 US clinical trials tracked, 79 recruiting.

Type 1 Diabetes is the subject of 199 registered US clinical trials on ClinicalTrials.gov, 79 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 16 of these trials.

Enrollment posture brief

Registry condition type-1-diabetes

OPEN 79 | RECR 40% | LATE 21 | EARLY 54 | RANK #50 | SPON 16

Nearest open-share peer: Pregnancy (40% recruiting · 194 trials)

Solid Tumor52.8%Type 1 Diabetes (this)40%Glioblastoma39%Overweight25.3%Rheumatoid Arthritis18.6%
Open-enrollment share among volume-matched conditions near Type 1 Diabetes

Type 1 Diabetes lists 79 open slots (40% of 199 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Type 1 Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Type 1 Diabetes is recruiting above its size-band peers.

    79 of 199 indexed trials (39.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Type 1 Diabetes trials is spread across many organizations.

    University of Colorado, Denver accounts for 16 of 199 trials (8%). 97 distinct sponsors appear on at least one study for this condition label.

  3. Most Type 1 Diabetes trials plan to enrol fewer than 100 people.

    Median target enrolment is 43 among the 199 trials that report a genuine target (sentinel values excluded). 141 of those (70.9%) plan for fewer than 100 participants.

  4. Type 1 Diabetes research is mostly interventional.

    169 interventional and 30 observational studies make up this index (84.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 130Phase 224Phase 311Phase 410

Open and recent trials

199 total, page 3 of 4

ACTIVE NOT RECRUITING Phase 2 30 participants

Effects of GRA in Patients With Type 1

University of California, San Diego

NCT04779645

ACTIVE NOT RECRUITING 28 participants

Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes

AdventHealth Translational Research Institute

NCT04164966

ACTIVE NOT RECRUITING NA 28 participants

Community Health Workers in Pediatric Patients With Newly Diagnosed Type 1 Diabetes

Children's Hospital of Philadelphia

NCT04238949

ACTIVE NOT RECRUITING NA 20 participants

A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D)

Milton S. Hershey Medical Center

NCT06640478

ACTIVE NOT RECRUITING Early Phase 1 11 participants

Adrenergic System in Islet Transplantation

University of Pennsylvania

NCT03079921

ACTIVE NOT RECRUITING Phase 1 7 participants

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Vertex Pharmaceuticals Incorporated

NCT05791201

COMPLETED NA 32,796 participants

Extension for Community Health Outcomes (ECHO) Diabetes Program

University of Florida

NCT06552923

COMPLETED Phase 1 1,298 participants

Family Management of Childhood Diabetes Study

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT00340938

COMPLETED Phase 3 692 participants

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Eli Lilly and Company

NCT05463744

COMPLETED 649 participants

A 2-Month Safety Follow-Up Trial

Mannkind Corporation

NCT00741429

COMPLETED NA 568 participants

Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)

University of Virginia

NCT01563887

COMPLETED NA 485 participants

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

Medtronic Diabetes

NCT00417989

COMPLETED Phase 3 451 participants

Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes

Jaeb Center for Health Research

NCT00406133

COMPLETED NA 300 participants

Sweetgoals for Type 1 Diabetes

Trustees of Dartmouth College

NCT04646473

COMPLETED 164 participants

Investigation Into the Effects Upon Brain Response to Change in Circulating Glucose Levels in Diabetes Mellitus

Yale University

NCT00580710

COMPLETED 154 participants

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

HealthPartners Institute

NCT00945711

COMPLETED Phase 3 130 participants

Automated Insulin Delivery for Inpatients With Dysglycemia

Emory University

NCT06418880

COMPLETED NA 130 participants

Can Glucose Monitoring Improve (CGMi Study)

Joslin Diabetes Center

NCT01472159

COMPLETED NA 127 participants

Testing MST to Improve Adherence Among Youth With Chronic Poor Metabolic Control

Wayne State University

NCT00519935

COMPLETED Phase 2 115 participants

ADJUnct Semaglutide Treatment in Type 1 Diabetes

Viral N. Shah

NCT05537233

COMPLETED Phase 3 113 participants

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

Jaeb Center for Health Research

NCT04233034

COMPLETED Phase 2 108 participants

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes

University of Colorado, Denver

NCT02544321

COMPLETED NA 107 participants

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

University of Florida

NCT01621776

COMPLETED NA 80 participants

In Clinic Evaluation of the PLGM Feature

Medtronic Diabetes

NCT02130284

COMPLETED Phase 4 70 participants

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

Gianna Wilkie

NCT04599075

COMPLETED 70 participants

Assessment of Sleep and Sleep Disruptors in Adolescents With Type 1 Diabetes

University of Colorado, Denver

NCT05370339

COMPLETED Phase 2 63 participants

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Mesoblast

NCT00690066

COMPLETED NA 62 participants

Iterative Beta Testing of Videos for the DIPPer Academy

University of Kansas Medical Center

NCT03385265

COMPLETED Early Phase 1 60 participants

Early Markers of Disease and Response to Therapy

Sandra Lord, MD

NCT04118153

COMPLETED Phase 4 60 participants

Lantus in the Treatment of Type 1 Diabetes Children

Baylor College of Medicine

NCT00206401

COMPLETED Phase 4 59 participants

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

University of Washington

NCT04623086

COMPLETED NA 59 participants

Insulet Artificial Pancreas Early Feasibility Study

Insulet Corporation

NCT02897557

COMPLETED Phase 1 57 participants

Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System

Jaeb Center for Health Research

NCT01271023

COMPLETED NA 55 participants

Eating Disorder Prevention Program for Women With T1D

Stanford University

NCT05264376

COMPLETED Phase 2 50 participants

Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation

University of California, Davis

NCT00441844

COMPLETED NA 50 participants

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

University of Virginia

NCT04877730

COMPLETED 50 participants

Development of Predictive Biomarkers

Medical College of Wisconsin

NCT03423862

COMPLETED Phase 2 48 participants

Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

Benjamin U. Nwosu, MD

NCT03046927

COMPLETED NA 48 participants

Hypoglycemia Associated Autonomic Failure in Type 1 DM

Vanderbilt University

NCT00592670

COMPLETED 46 participants

Analysis of B Cells From Autoimmune Individuals

University of Colorado, Denver

NCT02747277

COMPLETED 46 participants

Impact of Hybrid Closed-Loop Systems on Sleep and Psychosocial Outcomes in Youth With T1D and Their Parents

University of Colorado, Denver

NCT04431947

COMPLETED Phase 4 45 participants

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

University of Colorado, Denver

NCT02502071

COMPLETED NA 41 participants

School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus

State University of New York - Upstate Medical University

NCT00566475

COMPLETED NA 39 participants

HCT Cash-Only INcentive to Promote Mealtime Insulin DOSE Engagement

Children's Mercy Hospital Kansas City

NCT04621890

COMPLETED NA 39 participants

Promoting Adolescent Investment In Diabetes Care

Harvard Pilgrim Health Care

NCT04516694

COMPLETED NA 39 participants

Self-Management in Young Adults With Type 1 Diabetes

Case Western Reserve University

NCT04975230

COMPLETED NA 38 participants

Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes

Nationwide Children's Hospital

NCT01724190

COMPLETED Phase 4 36 participants

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

Baylor College of Medicine

NCT00340613

COMPLETED NA 35 participants

Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control

Joslin Diabetes Center

NCT02556398

COMPLETED NA 34 participants

Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA

University of Minnesota

NCT02829593

← Previous Page 3 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 30
Phase 2 24
Phase 3 11
Phase 4 10

Named interventions

Most-linked intervention names on Type 1 Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
18 trials
Placebo Other
8 trials
Diabetes Education Behavioral
3 trials
Insulin Degludec Drug
2 trials
Diabetes Body Project Behavioral
2 trials
Digital resources for diabetes Behavioral
2 trials
FAMS-T1D Behavioral
2 trials
REMD-477 Drug
2 trials

US sites by state

Facility locations filed on Type 1 Diabetes trials. A trial with sites in several states counts in each.

California 48 trials
Colorado 37 trials
Massachusetts 25 trials
Virginia 21 trials
Florida 21 trials
Minnesota 18 trials
Connecticut 16 trials
New York 15 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Type 1 Diabetes page

199 registered trials, 79 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 1 Diabetes condition card totals 199 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.